Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax in May had signed a deal worth at least ... were placed on the U.S. Food and Drug Administration's ability to review products. Its net loss was $81 million for the quarter ended December ...

Shares of Novavax Inc. NVAX slipped 3.24% to $7.17 Tuesday, on what proved to be an all-around mixed trading session for the ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%. Feb-25 8.5 calls and Mar-25 7.5 puts are the most active ...